GLP-1 medications and medical supervision: what the evidence says

What's this video probably claiming?

Based on the caption "Use medicações com orientações médicas" (Use medications with medical guidance) and the GLP-1 category tag, this creator is almost certainly discussing semaglutide, tirzepatide, or a related GLP-1 receptor agonist, likely in the context of weight loss. The message appears to be a pro-medical-supervision stance, which is a reasonable position, but these videos often blur into territory where creators present GLP-1s as broadly safe, universally effective, or straightforward to use. The Portuguese-language caption suggests a Brazilian audience, where off-label compounded GLP-1 use has exploded in recent years alongside a parallel social media frenzy. The creator's username and the 7.7K view count suggest a mid-tier health influencer, not a peer-reviewed source. Whether the video leans educational or promotional is unclear without the transcript, but the framing warrants scrutiny.

What does the science actually show?

GLP-1 receptor agonists have real, well-documented efficacy. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced a mean 14.9% body weight reduction over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced a mean 20.9% weight reduction over 72 weeks. These are not trivial numbers. But the data also shows that roughly 75-80% of weight lost returns within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism). GLP-1 medications also carry real adverse effect profiles: nausea affects up to 44% of users, and rare but serious risks include pancreatitis, gallbladder disease, and thyroid C-cell concerns flagged by the FDA, particularly with long-duration use. Medical oversight is not optional theater. It is the entire point.

Where does the social media noise diverge from clinical reality?

The GLP-1 TikTok universe has a consistent set of distortions. First, creators routinely underemphasize that these drugs were designed for chronic use in people with obesity or type 2 diabetes, not as short-term body recomposition tools for people with a BMI under 30. Second, the compounded semaglutide conversation is rampant on social media, with users treating compounded versions as interchangeable with FDA-approved Wegovy or Ozempic. They are not. The FDA has explicitly stated that compounded semaglutide is not FDA-approved and carries risks related to dosing accuracy and sterility. Third, many creators present "medical guidance" as a checkbox, not a continuous relationship. Starting a GLP-1 without thyroid history review, personal or family history of MEN2, or pancreatitis screening is a real clinical failure, not a technicality.

What should you actually know?

If this video is genuinely advocating for physician-supervised GLP-1 use, that part is correct. But supervision quality matters enormously. A telehealth consultation that lasts four minutes and ends in a prescription is not the same as a structured clinical relationship that includes baseline labs, cardiovascular risk assessment, and a realistic conversation about what happens when the medication is stopped. Patients should know that GLP-1 medications are chronic disease tools, not courses you complete. The SCALE trial (Pi-Sunyer et al., 2015, NEJM) with liraglutide 3mg, and subsequent semaglutide data, both confirm that cessation leads to significant weight regain in most patients. Anyone prescribing or promoting these medications without discussing long-term adherence, insurance access, and exit strategy is giving an incomplete picture, regardless of how responsible the caption sounds.